ESMO Breast 2024 | Emerging mechanisms of resistance to endocrine therapies in HR+ breast cancer

Hiroji Iwata, MD, PhD, Nagoya City University, Nagoya, Japan, discusses emerging mechanisms of resistance to endocrine therapies in HR+ metastatic breast cancer. Key mechanisms include resistance following CDK4/6 inhibitor treatment and various gene alterations. These insights are crucial for understanding and addressing resistance in this patient population. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.